Heart failure & cardiomyopathies
Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation
Authors' conclusion
LVAD implantation was associated with reductions in systemic and tissue-specific cfDNA levels.
Study context
- Population
- Patients with advanced HF with and without durable LVAD; separate cohort with paired samples before and after LVADcohort 2: 40 paired
- Participants
- 76 / 144 / 48
- Exposure
- HF with LVAD vs without LVAD; before vs after LVAD; vs healthy controls
- LVADn = 76
- Without LVADn = 144reference
- Healthy controlsn = 48
- Outcome
- ncfDNA levels
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
P = 0.019
Observational data: associations, not effects.
Further findings
ncfDNA before vs after LVAD (cohort 2)
P < 0.001
Outcomes by highest pre-LVAD nuclear cfDNA (ncfDNA) tertile
| HR (95% CI) | P value | ||
|---|---|---|---|
| Highest tertileWorse infection-free survival | 2.94 (1.31–6.56) | P = 0.006 | |
| Highest tertileWorse hemocompatibility-related adverse event-free survival | 3.24 (1.03–10.3) | P = 0.034 | |
| 0.050.21520Hazard ratio (log scale) |
- Cell-free DNA (cfDNA), cohort 1 vs healthy controls · ncfDNA 4-fold higher: 9794 vs 2386 copies/mL
- P < 0.001
- cfDNA, cohort 1 vs healthy controls · mtDNA 1.5-fold higher: 134 707 vs 82 054 copies/mL
- P = 0.01
ncfDNA before vs after LVAD (cohort 2)
- Significant reductions in innate immune, vascular endothelium, gastrointestinal and liver cfDNA
Original publication
Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation. Circ Heart Fail. Published 27 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →